BKYI 10-K & 10-Q changes, risk factors and insider trading
Bio Key International Inc. · Nasdaq · Services-Prepackaged Software · CIK 1019034 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
New heading “Material weaknesses could materially and adversely affect our operations, financial condition, reputation and stock price.”
Removed heading “We identified a material weakness in our internal control over financial reporting related to the recording and processing of revenue transactions which required the restatement of our quarterly financial statements for the interim periods in 2023. Such material weaknesses could materially and adversely affect our operations, financial condition, reputation and stock price.”
Removed heading “Legal, regulatory or market measures to address climate change may materially and adversely affect our future results of operations and financial condition.”
Largest changes
“We identified a material weakness in our internal control over financial reporting related to the recording and processing of revenue transactions which required the restatement of our quarterly financial statements for the interim periods in 2023. Such material weaknesses could materially and adversely affect our operations, financial condition, reputation and stock price.”see in full comparison
“The short and long-term implications of Russia’s invasion of Ukraine, and the war between the US and Iran are difficult to predict at this time. We continue to monitor any adverse impact that the outbreak of war in Ukraine and the subsequent institution of sanctions against Russia by the U.S. and several European and Asian countries, which has not caused any material harm to the Company to date; along with the war in Iran, may have on the global economy in general, on our business and operations and on the businesses and operations of our suppliers and customers. …”see in full comparison
“Our common stock is listed for trading on Nasdaq. In order to maintain our listing, we must satisfy Nasdaq’s continued listing requirements. In 2024, we received multiple notices from Nasdaq indicating that we were not in compliance with Nasdaq continued listing requirements. These notices referenced failures to timely file our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, to timely file our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, and failure to maintain minimum stockholders' equity of at least $2.5 million. …”see in full comparison
“In connection with the audit of our financial statements for the year ended December 31,2023, management concluded that the Company’s previously issued consolidated financial statements should be restated due to inadvertently including certain revenue from our European subsidiary, Swivel Secure Europe, Ltd., in the first quarter of 2023. In addition, certain allowances for accounts receivable and certain reserves for inventory were understated. Therefore, the Company misstated gross revenues, accounts receivable, and inventory during the first three quarters of 2023. …”see in full comparison
“Material weaknesses could materially and adversely affect our operations, financial condition, reputation and stock price.”see in full comparison
“On May 13, 2026 trading of our common stock on Nasdaq was suspended due to our failure to regain compliance with the minimum bid requirement and to timely file our periodic reports with the SEC. Our common stock currently trades on OTC Markets under the symbol “BKYI”. On April 30, 2026, we effected a one-for-ten reverse stock split which restored our share price to a level in excess of Nasdaq’s $1 minimum closing bid price requirement. …”see in full comparison
Full comparison: every changed paragraph (21)
Material weaknesses could materially and adversely affect our operations, financial condition, reputation and stock price.
We identified a material weakness in our internal control over financial reporting related to the recording and processing of revenue transactions which required the restatement of our quarterly financial statements for the interim periods in 2023. Such material weaknesses could materially and adversely affect our operations, financial condition, reputation and stock price.
In connection with the audit of our financial statements for the year ended December 31,2023, management concluded that the Company’s previously issued consolidated financial statements should be restated due to inadvertently including certain revenue from our European subsidiary, Swivel Secure Europe, Ltd., in the first quarter of 2023. In addition, certain allowances for accounts receivable and certain reserves for inventory were understated. Therefore, the Company misstated gross revenues, accounts receivable, and inventory during the first three quarters of 2023. The restatement related to the Company’s material weakness in internal control over financial reporting over the recording of revenue, accounts receivable, and inventory transactions. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. We completed the restatement and have now corrected and continue to monitor the applied corrective actions to remediate the material weakness and continue to strengthen our internal controls over the recording of revenue transactions.
Based on our limited cash resources, history of significant losses, negative cash flow,flow from operations, and dependence on debt and equity financing to fund operations, our independent registered public accounting firm has included an explanatory paragraph in their opinion as to the substantial doubt about our ability to continue as a going concern.
Due to, among other factors, our history of significant losses, limited cash resources, negative cash flow,flow from operations, and dependence on debt and equity financing to fund operations, our independent registered public accounting firm has included an explanatory paragraph in their opinion for the year ended December 31, 20242025 as to the substantial doubt about our ability to continue as a going concern.concern within one year after issuance. Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States, which contemplate that we will continue to operate as a going concern. Our financial statements do not contain any adjustments that might result if we are unable to continue as a going concern.
WeHistorically, we have historically not generated significant revenue and have sustained substantial operating losses.
Our failure to timely file our annual report on Form 10-K for the year ended December 31, 2023 and our quarterly report on Form 10-Q for the period ended March 31, 20242025 has made us ineligible to use a Form S-3 to register the offer and sale of securities, which could adversely affect our ability to raise future capital.
As a result of our failure to timely file our annual report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on SEC Form 10-Q for the period ended March 31, 2024,2025 we are not eligible to register the offer and sale of our securities using a registration statement on Form S-3 until one year from the date we regain and maintain status as a current filer.filer, assuming that we remain listed on the Nasdaq Capital Market. Should we wish to register the offer and sale of our securities to the public prior to the time we are eligible to use Form S-3, both our transaction costs and the amount of time required to complete the transaction could increase, making it more difficult to execute any such transaction successfully and potentially harming our financial condition.
Any failure or perceived failure by us to comply with our privacy policies, our privacy-related obligations to customers or other third parties, or applicable laws or regulations relating to privacy, data protection, or information security may result in governmental investigations or enforcement actions, litigation, claims or public statements against us by consumer advocacy groups or others, and could result in significant liability or cause our customers to lose trust in us, which could cause them to cease or reduce use of our products and services and otherwise have an adverse effect on our reputation and business. Any similar failure or perceived failure by users of our products or services may also have an adverse effect on our reputation and business. In addition, legal, regulatory, contractual and other obligations as well as public concerns relating to privacy, data protection or information security could restrict our ability to store and process data as part of our solutions or otherwise impact our ability to provide our solutions in certain jurisdictions and may result in the loss of business opportunities from customers operating in, or seeking to expand into, those jurisdictions. Additionally, inwe 2023,are thesubject to SEC adopted new rules related to cybersecurity risk management, which may further increase our regulatory burden and the cost of compliance in such events.
Our business is subject to the imposition of tariffs and other trade barriers, which may make it more costly for us to import inventory from China and Hong Kong and certain product components from South Korea. The newcurrent presidential administration recentlyhas imposed new tariffs on imports to the United States from China, Mexico, Canada, and Europe and is expected tomay impose newadditional tariffs onin importsthe fromfuture. other countries. In addition, theseOther countries have, and in the future other countries may, impose retaliatory tariffs. The resulting environment of retaliatory trade or other practices or additional trade restrictions or barriers could harm our ability to obtain inventory and product components or sell our products and services at prices customers are willing to pay, which could have a material adverse effect on our business, prospects, results of operations, and cash flows. Relatedly, trade policies could lead to an increasing number of competitors entering the United States, thereby creating more competition. If we experience cost increases as a result of existing or future tariffs and are unable to pass on such additional costs to our customers, or otherwise mitigate the costs, our business, prospects, financial condition, results of operations, and cash flows could be materially and adversely affected.
Legal, regulatory or market measures to address climate change may materially and adversely affect our future results of operations and financial condition.
In March 2024, the SEC adopted climate disclosure rules, which would require new disclosure in certain SEC filings about material climate-related risks, activities to mitigate or adapt to such risks, board oversight of climate-related risks and management’s role in managing material climate-related risks, and climate-related targets and goals. These climate disclosure rules have been the subject of multiple legal challenges, and the SEC recently dropped its defense of the rules, so the extent to which the rules will go into effect remains uncertain. Inconsistency of regulations at the federal and state level may affect the costs of compliance with such legal or regulatory requirements. We may incur increased costs relating to the assessment and disclosure of climate-related risks and increased litigation risks related to such disclosures, either of which could materially and adversely affect our future results of operations and financial condition. Adverse publicity or climate-related litigation that impacts us could have a negative impact on our business.
The warimpact inof Ukrainethe Russian invasion of Ukraine, and the US-Iran war, and the international community’s response have created substantial political and economic disruption, uncertainty, and risk.
The short and long-term implications of Russia’s invasion of Ukraine, and the war between the US and Iran are difficult to predict at this time. We continue to monitor any adverse impact that the outbreak of war in Ukraine and the subsequent institution of sanctions against Russia by the U.S. and several European and Asian countries, which has not caused any material harm to the Company to date; along with the war in Iran, may have on the global economy in general, on our business and operations and on the businesses and operations of our suppliers and customers. Such risks include, but are not limited to, adverse effects on macro-economic conditions, including inflation; disruptions to our global technology infrastructure, including through cyberattack, ransom attack, or cyber-intrusion; adverse changes in international trade policies and relations; our ability to maintain or increase our product prices; disruptions in global supply chains; our exposure to foreign currency fluctuations; and constraints, volatility, or disruption in the capital markets, any of which could negatively affect our business and financial condition. These and related actions, responses, and consequences that cannot now be predicted or controlled may contribute to world-wide economic reversals.
Russia’s military intervention in Ukraine in late February 2022, Ukraine’s widespread resistance, and the NATO led and United States coordinated economic, financial, communications, and other sanctions imposed by other countries have created significant political and economic world uncertainty. It is not possible to predict the broader consequences of the conflict, including related geopolitical tensions, and the measures and retaliatory actions taken by the U.S. and other countries in respect thereof, as well as any counter measures or retaliatory actions by Russia in response. At a minimum, the continuing conflict is likely to cause regional instability, geopolitical shifts and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy, which could materially adversely affect our financial condition or results of operations. Current and likely additional international sanctions against Russia may contribute to higher costs, particularly for petroleum-based products. These and related actions, responses, and consequences that cannot now be predicted or controlled may contribute to world-wide economic reversals.
As of the date of this report, approximately 4,275,056794,073 shares of our common stock (as adjusted to reflect our 1-for-181-for-10 reverse stock split, which was effective DecemberApril 21,30, 20232026) were reserved for issuance upon exercise or conversion of outstanding stock options and warrants. The exercise or conversion of these securities will result in a significant increase in the number of outstanding shares and substantially dilute the ownership interests of our existing stockholders.
AlthoughOn May 13, 2026 trading of our common stock is listed on the Nasdaq Capital Market,Market was suspended which could adversely impact the trading and liquidity of our common stock. Our common stock currently trades on OTC Markets and an active trading market for our shares may not be developed on OTC Markets and if developed, sustained. If an active market for our common stock is not developed or sustained, it may be difficult for you to sell your shares without depressing the market price for the shares or sell your shares at all. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.
Trading of our common stock on the Nasdaq Capital Market was suspended on May 13, 2026. If we failare not successful in our appeal of Nasdaq’s decision and are unable to complyregain compliance with the continued listing requirements of The Nasdaq Stock Market, our Common Stock maywill be delisted and the price of our Common Stock and our ability to access the capital markets could be negatively impacted.
On May 13, 2026 trading of our common stock on Nasdaq was suspended due to our failure to regain compliance with the minimum bid requirement and to timely file our periodic reports with the SEC. Our common stock currently trades on OTC Markets under the symbol “BKYI”. On April 30, 2026, we effected a one-for-ten reverse stock split which restored our share price to a level in excess of Nasdaq’s $1 minimum closing bid price requirement. Due to the timing of the reverse split, we were unable to maintain this share price level for 10 consecutive trading days prior to May 6, 2026 which resulted in our shares being suspended from trading on Nasdaq. The suspension and potential delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock as shares traded on the OTC Markets generally have substantially less liquidity and it can be more difficult for stockholders and broker/dealers to purchase and sell our shares in an orderly manner or at all. As a result, the trading price of our common stock may change quickly, and brokers may not be able to execute trades as quickly as they previously could when our common stock was listed on a national exchange.. Delisting could also harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities. .
We have appealed Nasdaq’s decision to suspend trading in our common stock and are currently working to regain compliance with all continued listing standards of the Nasdaq Capital Market. A hearing to consider our appeal is currently scheduled for June 16, 2026. There can be no assurance that our appeal will be successful or that our shares will not be delisted.
Our common stock is listed for trading on Nasdaq. In order to maintain our listing, we must satisfy Nasdaq’s continued listing requirements. In 2024, we received multiple notices from Nasdaq indicating that we were not in compliance with Nasdaq continued listing requirements. These notices referenced failures to timely file our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, to timely file our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, and failure to maintain minimum stockholders' equity of at least $2.5 million. We have timely cured each of these deficiencies and are currently in compliance with Nasdaq’s continued listing standards. The value of the shares of common stock of Boumarang Inc. that we purchased from Fiber Food Systems, Inc. in connection with our collaboration with Fiber Food Systems increased our stockholders’ equity to a level which satisfied the Nasdaq minimum requirement. As a privately held pre-revenue company, Boumarang is subject to all of the risks and uncertainties inherent in an early-stage enterprise and the value of its shares are subject to fluctuation which could be material. Any material decrease in the value of these shares could cause us our stockholders’ equity to fall below the Nasdaq minimum requirement resulting in the potential delisting of our shares from the Nasdaq stock market. In addition, in recent weeks the trading price of our common stock has fallen below the $1.00 minimum bid required to maintain our listing on Nasdaq. Continued trading below $1.00 per share could subject us to delisting from the Nasdaq stock market. The delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. Delisting could also harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities
Management's Discussion & Analysis (MD&A)
New heading “Impairment of investment”
Largest changes
“For the year ended December 31, 2025 impairment of investment was $2,500,000 compared with $0 representing a 100% increase from 2024. The amount of $2,500,000 represents a 50% impairment of the investment based on expected revenue that has not occurred to date.”see in full comparison
Reflectingsee in full comparisonincreaseddecreased gross profit andloweranoperatingimpairmentexpenses,expense, net lossimprovedincreased to $(4,300,6927,157,946) in20242025 from a net loss of $(8,521,8374,300,692) in2023.2024.
“On June 24, 2024, we entered into and closed a note purchase agreement which provided for the issuance of a $2,360,000 principal amount senior secured promissory note (the "2024 Note"). This resulted in gross proceeds of approximately $1,826,000 after deducting placement agent fees, estimated offering expenses, and the original issue discount. …”see in full comparison
“On September 12, 2024, we entered into a warrant exercise agreement with the investor to exercise certain outstanding warrants to purchase an aggregate of 103,056 shares of common stock. The warrants were originally issued to the investor on October 31, 2023 and had an original exercise price of $31.50 per share. In consideration for the immediate exercise of these warrants, we reduced the exercise price of the warrants to $18.50 per share and issued to the Investor additional warrants to purchase an aggregate of 206,112 shares of common stock at an exercise price of $18.50 per share. …”see in full comparison
“The amounts for other income (expense) for the year ended December 31, 2024 consisted of interest income of $110, interest expense of $175,755 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $124,000. …”see in full comparison
Full comparison: every changed paragraph (28)
All share totals reported herein have been adjusted to reflect our 1-for-181-for-10 reverse stock split, which was effective DecemberApril 21,30, 2023.2026.
Revenue decreased $825,334$922,016 or 11%142% to $5,937,555 in 2025 as compared to $6,929,571 in 2024 as compared to $7,754,905 in 2023.2024. This reduction was due largely to a significant contract renewal with a foreign retail bank that benefited 2024 that did not recur in 2025 and due to our exit from our distribution agreement with Swivel Secure Limited (SLL) and transition to selling BIO-key branded solutions in the EMEA market and to the factors discussed below.
For the years ended December 31, 2024,2025, and 2023,2024, service revenues included approximately $1,017.000$1,060,000 and $1,193,000,$1,017,000, respectively, of recurring maintenance and support revenue, and approximately $91,000$112,000 and $1,026,000,$91,000, respectively, of non-recurring custom services revenue. Recurring service revenue decreasedincreased 15%4% in 20242025 due to the loss of one largegrowing customer service agreement.base. Non-recurring custom services decreasedincreased 91%23% in 20242025 due to aseveral largenew productcustomers customizationrequiring andsupported upgrade for a Swivel Secure customer without a similar customization in 2024.deployments. We expect the service fees to increase from the current levels as we expand our deployments worldwide.
For the years ended December 31, 2025 and 2024 license revenue decreased $1,766,070 or 34% to $3,423,300, due largely to a significant contract renewal with a foreign retail bank that benefited 2024 hat did not recur in 2025, and due to the ramp up of BIO-key EMEA selling only BIO-key product.
Hardware sales increased by $710,453, or 112%, to $1,342,148 in 2025 from $631,695 in 2024. The increase was attributable to several long-term and new customers expanding their purchase of biometric cybersecurity solutions combined with selling some of fully reserved inventory from the African project.
For the year ended December 31, 2024 and 2023 license revenue increased $847,360 or 20% to $5,189,370, as several long-term customers expanded their license deployments in addition to several new customer deployments. We expect this trend to continue into 2025.
Hardware sales decreased by $562,315, or 47%, to $631,695 in 2024 from $1,194,010 in 2023. The decrease was attributable largely to fourth quarter 2023 sales to an international defense agency that did not reoccur in 2024.
Hardware costs for the year ended December 31, 2024 decreasedincreased $183,620,$672,853, or approximately 26%,130%, to $516,611$1,189,464 from $700,231$516,611 in 2023.2024. The decreaseincrease was associated with the decreasedincreased hardware sales and hardware mix. Hardware reserve costs for the year ended December 31, 20242025 decreasedincreased $3,799,505$300,395, dueor approximately 141% from $(213,005) to sales$(513,400) which represented a removal of slow-movingthe inventory after a completeentire reserve for sales of slow-moving inventory purchased for projects in Nigeria, and for other older inventoryinventory. We were successful in 2023.our We are continuing to explore other markets and opportunitiesefforts to sell the slow-moving inventory.
Gross profit increaseddecreased to $4,564,518 in 2025 from $5,640,186 in 2024 from $1,431,319 in 2023,2024, due to a $3,000,000 hardware reserve taken in 2023, the impact of growth in higher-marginlower license sales,fee revenue, and aan reductionincrease in lower-margin services and hardware revenue.
Selling, general and administrative costs for year ended December 31, 20242025 were $6,282,232 compared to $7,140,147 in 2024 compared to $7,862,7102024, representing aan 9%12% decrease from 2023.decrease. The decrease was due to proactivea costreorganization reductions including reductions in headquarters expenses,of sales personnel costs, lower marketing show expenses, and audit fees which were partially offset by an increase in professional services, principally related to financing activities in 2024.2025.
Impairment of investment
For the year ended December 31, 2025 impairment of investment was $2,500,000 compared with $0 representing a 100% increase from 2024. The amount of $2,500,000 represents a 50% impairment of the investment based on expected revenue that has not occurred to date.
The amounts for other income (expense) for the year ended December 31, 2025 consisted of interest income of $3,787, interest expense of $60,793 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $256,833. The amounts for the year ended December 31, 2024, consisted of interest income of $110, interest expense of $175,755 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $124,000.
The amounts for other income (expense) for the year ended December 31, 2024 consisted of interest income of $110, interest expense of $175,755 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $124,000. The amounts for the year ended December 31, 2023, consisted of interest income of $11,533, a gain from the sale of a PistolStar domain asset, change in loan transactions costs for payment of the convertible note payable as we elected to value the convertible note under the fair value option, and interest expense of $218,270 on the convertible note payable and the government loan through the BBVA bank.
Reflecting increaseddecreased gross profit and loweran operatingimpairment expenses,expense, net loss improvedincreased to $(4,300,6927,157,946) in 20242025 from a net loss of $(8,521,8374,300,692) in 2023.2024.
Approximately $3,908,000$7,967,000 was provided by financing activities during the year ended December 31, 20242025 consisting of the proceeds of $1,000,000 advanced under a secured note, proceeds from the exercise of warrants,warrants totaling approximately $6,500,000, and $3,740$10,076 from sales of common stock under our employee stock purchase plan. These amounts were offset by a partial repayment of note payable, repayment of a government loan, and costs associated with the issuance of our securities.
On January 15, 2025, we entered into a warrant exercise agreement with an existing institutional investor (the “Investor”) to exercise certain outstanding warrants to purchase an aggregate of 2,061,112 shares of common stock at an exercise price of $1.85 per share which were originally issued to the Investor on September 13, 2024. In consideration for the exercise of these warrants, we issued new warrants to the Investor to purchase an aggregate 3,091,668 shares of common stock at an exercise price of $2.15 per share. We realized gross proceeds of approximately $3.8 million, prior to deducting placement agent fees and estimated offering expenses.
On SeptemberOctober 12,27, 2024,2025, we entered into and closed a warrant exercise agreement with thean Investorexisting institutional investor to exercise certain outstanding warrants to purchase an aggregate of 1,030,5563,091,668 shares of common stock. The warrants were originally issued to the Investor on OctoberJanuary 31,15, 20232025 and had an original exercise price of $3.15$2.15 per share. In consideration for the immediate exercise of these warrants, we reduced the exercise price of the warrants to $1.85 per share and issued tonew the Investor additionalunregistered warrants to purchase up to an aggregate of 2,061,1126,183,336 shares of common stock at an exercise price of $1.85$1.02. perWe share. The forgoing transaction resulted inrealized gross proceeds of approximately $1.9$3.1 millionmillion, prior to deducting placement agent fees and estimated offering expenses.
On JuneSeptember 24,30, 2024,2025, we entered into and closed a note purchase agreement which provided for the issuance of a $2,360,000$1,130,000 principal amount senior secured promissory note (the "20242025 Note"). This resulted in gross proceeds of approximately $1,826,000$1,000,000 after deducting placement agent fees, estimated offering expenses, and the original issue discount. The 20242025 Note is due eighteen months (18) following the date of issuance, accrues interest at a rate of nine percent (9%) per annum, and commencing six months after the date of issuance of,issuance, the lender shall have the right to redeem up to $270,000$135,000 of principal amount each month. In connection with the October 27, 2025 warrant exercise agreementsagreement described above, we prepaid approximately $762,600$450,000 of the amount due under the 20242025 Note. Pursuant to a series of exchange agreements in January 2025, the lender exchanged $859,000 principal amount due under the 2024 Note for 504,605 shares of common stock. As of the date of this report, the outstanding principal amount due under the 20242025 Note is $738,400.approximately $675,000. For a more complete description of the 20242025 Note, please see Note J to Ourour Consolidated Financial Statements included in Part II Item 8 of this report.
On January 15, 2025, we entered into a warrant exercise agreement with an existing institutional investor to exercise certain outstanding warrants to purchase an aggregate of 206,112 shares of common stock at an exercise price of $18.50 per share which were originally issued to the Investor on September 13, 2024. In consideration for the exercise of these warrants, we issued new warrants to the investor to purchase an aggregate 309,167 shares of common stock at an exercise price of $21.50 per share. We realized gross proceeds of approximately $3.8 million, prior to deducting placement agent fees and estimated offering expenses.
On September 12, 2024, we entered into a warrant exercise agreement with the investor to exercise certain outstanding warrants to purchase an aggregate of 103,056 shares of common stock. The warrants were originally issued to the investor on October 31, 2023 and had an original exercise price of $31.50 per share. In consideration for the immediate exercise of these warrants, we reduced the exercise price of the warrants to $18.50 per share and issued to the Investor additional warrants to purchase an aggregate of 206,112 shares of common stock at an exercise price of $18.50 per share. The forgoing transaction resulted in gross proceeds of approximately $1.9 million prior to deducting placement agent fees and estimated offering expenses.
On June 24, 2024, we entered into and closed a note purchase agreement which provided for the issuance of a $2,360,000 principal amount senior secured promissory note (the "2024 Note"). This resulted in gross proceeds of approximately $1,826,000 after deducting placement agent fees, estimated offering expenses, and the original issue discount. The 2024 Note was due eighteen months (18) following the date of issuance, accrues interest at a rate of nine percent (9%) per annum, and commencing six months after the date of issuance of, the lender shall have the right to redeem up to $270,000 of principal amount each month. In connection with the warrant exercise agreements described above, we prepaid approximately $762,600 of the amount due under the 2024 Note. Pursuant to a series of exchange agreements in January 2025, the lender exchanged $859,000 principal amount due under the 2024 Note for 50,461 shares of common stock. As of the date of this report, the 2024 Note is fully paid. For a more complete description of the 2024 Note, please see Note J to Our Consolidated Financial Statements included in Part II Item 8 of this report.
On November 20, 2023, we completed a private placement of shares of common stock and warrants resulting in net proceeds of approximately $435,000, after deducting placement agent fees and estimated offering expenses.
On October 30, 2023, we completed a public offering of shares of common stock and warrants resulting in net proceeds of approximately $3.3 million, after deducting placement agent fees and estimated offering expenses. We used approximately $2.2 million of the net proceeds to repay the outstanding amount due under outstanding convertible note payable.
At December 31, 2024,2025, our total cash and cash equivalents were approximately $438,000,$2,694,000, as compared to $511.000$438,000 at December 31, 2023. As of the date of this report, our total cash and cash equivalents are approximately $3,000,000.2024.
As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $812,000$750,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. During 2024,2025, we generated approximately $6,930,000$5,900,000 of revenue, which did not generate enough cash to fully fund our average monthly cash requirements. The 2024 Note is due on or about December 24, 2025 and we are subject to monthly redemptions request at the option of the lender. We also have approximately $3.4$2.9 million of inventory (currently reserved) purchased for projects in Nigeria. We continue to explore other markets and opportunities to sell or return the product to continue to generate additional cash.
New Accounting Pronouncements
See Note A Item 16, “Recent Adopted Accounting Pronouncements” and Note A Item 17, “Recent Issued Accounting Pronouncements,” of the Consolidated Financial Statements for additional information about new accounting pronouncements.
What changed in the latest 10-Q
Risk Factors
As a smaller reporting company, we are not required to provide the information required by this Item.
Investors are encouraged to consider the risks described in our 2025 Form 10-K/A, our Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this Report, and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.
Full comparison: every changed paragraph (1)
Investors are encouraged to consider the risks described in our 2025 Form 10-K,10-K/A, our Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this Report, and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.
Management's Discussion & Analysis (MD&A)
New heading “six MONTHS ENDED June 30, 2026 AS COMPARED TO June 30, 2025”
New heading “Consolidated Results of Operations - Percent Trend”
New heading “Revenues and cost of goods sold”
Removed heading “Costs and other expenses”
Removed heading “Other income (expense)”
Largest changes
“On September 12, 2024, we entered into a warrant exercise agreement with an existing investor to exercise certain outstanding warrants to purchase an aggregate of 103,056 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026). The warrants were originally issued to the Investor on October 31, 2023 and had an original exercise price of $31.50 per share. …”see in full comparison
Full comparison: every changed paragraph (34)
For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K/A for the year ended December 31, 2025. There have been no material changes to our critical accounting policies and estimates from those disclosed in our most recent Annual Report on Form 10-K.10-K/A.
THREE MONTHS ENDED MarchJune 31,30, 2026 AS COMPARED TO MarchJune 31,30, 2025
For the three months ended MarchJune 31,30, 2026, and 2025, service revenues included approximately $229,000$227,000 and $265,000,$271,000, respectively, of recurring maintenance and support revenue, and approximately $19,000$4,000 and $8,000$51,000 respectively, of non-recurring custom services revenue. Recurring service revenue decreased $36,000$44,000 or 14%16% in 2026 which was due to the timing of renewals of service agreements. Non-recurring custom services increaseddecreased $11,000$47,000 due to a small increasedecrease in customization. Overall, service revenues decreased to $248,384$231,005 as compared to $272,598$321,996 in the corresponding period in 2025.
For the three months ended MarchJune 31,30, 2026, license revenue increased $267,135$423,258 or 24%53% to $1,365,893$1,229,345 from $1,098,758$806,087 in the corresponding period in 2025 as several long-termnew customers expandeddeployed theirnew license deploymentslicenses in 2026.
For the three months ended MarchJune 31,30, 2026, hardware sales increaseddecreased 125%19% to $531,256$459,641 from $235,803$568,824 in the corresponding period in 2025. The increasedecrease was due to a large deployment from one long-term customer, several customer deploys of fully reserved inventory in the 2026 period, and one large deployment from one long-term customer and several long-term customers expanding their deployments of biometric cybersecurity solutions.solutions in 2025.
Costs and other expenses
For the three months ended MarchJune 31,30, 2026, cost of service decreased $19,646$38,585 or 20%33% to $78,498$79,716 from $98,114$118,301 in the three months ended MarchJune 31,30, 2025. For the three months ended MarchJune 31,30, 2026, license feescosts remaineddecreased relatively flat increasing less than one percent13% to $73,234$74,972 from $72,885$86,488 in the three months ended MarchJune 31,30, 2025,2025. For the three months ended MarchJune 31,30, 2026, hardware costs increaseddecreased to net cost of $224,568$91,263 (after giving effect to the $98,970$703,050 reversal of the reservepreviously forfully reserved inventory) from $108,469$259,391 in the three months ended MarchJune 31,30, 2025, for a net increasedecrease of 100%,65%, based on the increasedecrease in hardware revenue.revenue and different models of hardware shipped.
Selling, general and administrative expenses for the three months ended MarchJune 31,30, 2026, decreased 5%7% from $1,372,524$1,680,550 in the corresponding period in 2025 to $1,310,066$1,563,027 in the current quarter. The decreases included reductions in administration and professional services fees.fees, offset by one-time costs incurred in connection with our reverse split and increases in our accrued audit expenses and accrued taxes.
For the three months ended MarchJune 31,30, 2026, research, development, and engineering costs increased 4%1% to $616,880$640,418 compared to $595,775$636,027 in the corresponding period in 2025. The increase consisted primarily of professional services and personnel costs.
Other income (expense)
Other income (expense) for the three months ended MarchJune 31,30, 2026 consisted of interest income of $675,$386, interest expense of $27,166$27,000 on the note payable and the government loan through the BBVA bank,payable, and a loan fee amortization amount of $20,833. Other income (expense) for the three months ended MarchJune 31,30, 2025 consisted of interest income of $3$2,092 and interest expense of $35,910$25,638 comprised of the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $60,000.
six MONTHS ENDED June 30, 2026 AS COMPARED TO June 30, 2025
Consolidated Results of Operations - Percent Trend
Revenues and cost of goods sold
For the six months ended June 30, 2026, and 2025, service revenues included approximately $456,000 and $535,000, respectively, of recurring maintenance and support revenue, and approximately $23,000 and $59,000 respectively, of non-recurring custom services revenue. Recurring service revenue decreased $79,000 or 15% in 2026 which was due to the timing of renewals of service agreements. Non-recurring custom services decreased $36,000 due to a decrease in customization. Overall, service revenues decreased to $479,388 as compared to $594,594 in the corresponding period in 2025.
For the six months ended June 30, 2026, license revenue increased $690,393 or 36% to $2,595,238 from $1,904,845 in the corresponding period in 2025 as several new customers initiated license deployments in 2026.
For the six months ended June 30, 2026, hardware sales increased 186% to $990,898 from $804,627 in the corresponding period in 2025. The increase was due to a large deployment from one long-term customer, sales of fully reserved inventory, and several new customer deployments of biometric cybersecurity solutions in the 2026 period.
For the six months ended June 30, 2026, cost of service decreased $58,231 or 27% to $158,214 from $216,445 in the six months ended June 30, 2025. For the six months ended June 30, 2026, license costs decreasing to $148,206 from $159,373 in the six months ended June 30, 2025. For the six months ended June 30, 2026, hardware costs decreased to net cost of $315,831 (after giving effect to the $802,020 reversal of the fully reserved shipped inventory) from $367,860 in the six months ended June 30, 2025, for a net decrease of 14%, based on the increase in hardware reserve expense exceeding the increase of the hardware expense.
Selling, general and administrative expenses for the six months ended June 30, 2026, decreased 6% from $3,053,074 in the corresponding period in 2025 to $2,873,093 in the six months. The decreases included reductions in administration and professional services fees.
For the six months ended June 30, 2026, research, development, and engineering costs increased 2% to $1,257,299 compared to $1,231,802 in the corresponding period in 2025. The increase consisted primarily of professional services and personnel costs.
Other income (expense) for the six months ended June 30, 2026 consisted of interest income of $1,062, interest expense of $54,166 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $41,666. Other income (expense) for the six months ended June 30, 2025 consisted of interest income of $2,095 and interest expense of $61,548 comprised of the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $120,000.
Net cash used by financing activities during the threesix months ended MarchJune 31,30, 2026 was $38,179$30,519 consisting of the repayment of $38,179 government loan through the BBVA bank.bank, offset by receipt of $7,660 cash for the purchases under the Employee Stock Purchase Plan.
There was no cash used in investing activities during the threesix months ended MarchJune 31,30, 2026 .2026.
The following sets forth our sources of liquidity during the previous two years through the date of this filling:
On OctoberAugust 27,11, 2025,2026, we entered into and closed a warrant exercise agreementtransaction with an existing institutional investor to exercise certain outstanding warrants to purchase an aggregate of 309,167 shares of common stock(as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026). The warrants were originally issued on January 15, 2025 and had an exercise price of $21.50 per share. In consideration for the immediate exercise of these warrants, we issued new unregistered warrants to purchase up to an aggregate of 618,334 shares of common stock atin consideration for reducing the per share exercise price from $10.20 to $4.06 and issuing additional warrants to the investor to purchase up to an aggregate of 1,236,668 shares of common stock at exercise price of $10.20.$4.06 Weper realizedshare. The forgoing resulted in gross proceeds of approximately $3.1$2.5 million, prior to deducting placement agent fees and estimated offering expenses.
On September 30, 2025, we entered into and closed a note purchase agreement which provided for the issuance of a $1,130,000 principal amount senior secured promissory note (the "2025 Note"). This resulted in gross proceeds of approximately $1,000,000 after deducting estimated offering expenses, and the original issue discount. The 2025 Note is due eighteen months (18) following the date of issuance, accrues interest at a rate of nine percent (9%) per annum, and commencing six months after the date of issuance, the lender shall have the right to redeem up to $135,000 of principal amount each month. In connection with the October 27, 2025 warrant exercise agreement described above, we prepaid approximately $450,000 of the amount due under the 2025 Note. As of the date of this report, the outstanding principal amount due under the 2025 Note is approximately $675,000. For a more complete description of the 2025 Note, please see Note 10 to Our Condensed Consolidated Financial Statements included in Part I Item 1 of this report.
On January 15, 2025, we entered into a warrant exercise agreement with an existing investor to exercise certain outstanding warrants to purchase an aggregate of 206,112 shares of common stock, at an exercise price of $18.50 per share which were originally issued to the investor on September 12, 2024 (the "Existing Warrants"). In consideration for the exercise of the Existing Warrants, the investor received new warrants to purchase up to an aggregate of 309,167 shares of Common Stock ("New Warrants"). The New Warrants have substantially the same terms, are immediately exercisable at an exercise price of $21.50 per share and will expire five years from the date of issuance. The gross proceeds to the Company were approximately $3.8 million, prior to deducting placement agent fees and estimated offering expenses.
On SeptemberOctober 12,27, 2024,2025, we entered into and closed a warrant exercise agreement with an existing institutional investor to exercise certain outstanding warrants to purchase an aggregate of 103,056309,167 shares of common stock.stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026). The warrants were originally issued to the Investor on OctoberJanuary 31,15, 20232025 and had an original exercise price of $31.50$21.50 per share. In consideration for the immediate exercise of thethese warrants, we reducedissued thenew exercise price of theunregistered warrants to $18.50purchase per share and issuedup to the Investor unregistered Series A Warrants to purchase an aggregate of 103,056618,334 shares of common stock and(as unregistered Series B Warrantsadjusted to purchasereflect anour aggregate1-for-10 ofreverse 103,056stock sharessplit, ofwhich commonwas stock,effective eachApril with30, an exercise price of $18.50 per share and issued additional warrants to purchase an aggregate of 206,112 shares of common stock,2026) at an exercise price of $18.50$10.20. perWe share. The forgoing transaction resulted inrealized gross proceeds of approximately $1.9$3.1 millionmillion, prior to deducting placement agent fees and estimated offering expenses.
On September 30, 2025, we entered into and closed a note purchase agreement which provided for the issuance of a $1,130,000 principal amount senior secured promissory note (the "2025 Note"). This resulted in gross proceeds of approximately $1,000,000 after deducting estimated offering expenses, and the original issue discount. The 2025 Note is due eighteen months (18) following the date of issuance, accrues interest at a rate of nine percent (9%) per annum, and commencing six months after the date of issuance, the lender shall have the right to redeem up to $135,000 of principal amount each month. In connection with the October 27, 2025 warrant exercise agreement described above, we prepaid approximately $450,000 of the amount due under the 2025 Note.
On July 28, 2026, the Company entered into an Exchange Agreement (the “2025 Exchange Agreement”) with the Lender of the 2025 Note. Pursuant to the 2025 Exchange Agreement, the Company and Lender agreed to (i) partition from the 2025 Note a new Promissory Note (the “Partitioned Note”) in the original principal amount of $200,000, (ii) cause the outstanding balance of the 2025 Note to be reduced by $200,000 and (iii) exchange the Partitioned Note for 43,308 shares of the Company’s Common Stock, which was effective April 30, 2026). On August 10, 2026, the Company entered into a second exchange agreement with the Lender of the 2025 Note. Pursuant to this exchange agreement, the Company and Lender agreed to (i) partition from the 2025 Note a new Promissory Note (the “Second Partitioned Note”) in the original principal amount of $150,000, (ii) cause the outstanding balance of the 2025 Note to be reduced by $150,000 and (iii) exchange the Second Partitioned Note for 37,792 shares of the Company’s Common Stock . As of the date of this report, the outstanding principal amount due under the 2025 Note is approximately $325,000. For a more complete description of the 2025 Note, please see Note 10 to Our Condensed Consolidated Financial Statements included in Part I Item 1 of this report.
On January 15, 2025, we entered into a warrant exercise agreement with an existing investor to exercise certain outstanding warrants to purchase an aggregate of 206,112 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026), at an exercise price of $18.50 per share which were originally issued to the investor on September 12, 2024 (the "Existing Warrants"). In consideration for the exercise of the Existing Warrants, the investor received new warrants to purchase up to an aggregate of 309,167 shares of Common Stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026), ("New Warrants"). The New Warrants have substantially the same terms, are immediately exercisable at an exercise price of $21.50 per share and will expire five years from the date of issuance. The gross proceeds to the Company were approximately $3.8 million, prior to deducting placement agent fees and estimated offering expenses.
On September 12, 2024, we entered into a warrant exercise agreement with an existing investor to exercise certain outstanding warrants to purchase an aggregate of 103,056 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026). The warrants were originally issued to the Investor on October 31, 2023 and had an original exercise price of $31.50 per share. In consideration for the immediate exercise of the warrants, we reduced the exercise price of the warrants to $18.50 per share and issued to the Investor unregistered Series A Warrants to purchase an aggregate of 103,056 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026), and unregistered Series B Warrants to purchase an aggregate of 103,056 shares of common stock(as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026), each with an exercise price of $18.50 per share and issued additional warrants to purchase an aggregate of 206,112 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026), at an exercise price of $18.50 per share. The forgoing transaction resulted in gross proceeds of approximately $1.9 million prior to deducting placement agent fees and estimated offering expenses.
We enteredare intoparty to an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2026 and may be discontinued at that time. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us, with the remaining balance, less fees, forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.
At MarchJune 31,30, 2026, our total cash and cash equivalents were $2,247,984,$1,379,300, as compared to $2,694,663 at December 31, 2025. At MarchJune 31,30, 2026, we had a working capital of approximately $1,296,000.$793,000.
BKYI insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-30 | Sullivan James David |
Grant/award | 250 | $3.83 | $958 |
| 2026-06-30 | Depasquale Michael W |
Grant/award | 250 | $3.83 | $958 |
| 2026-06-30 | Lacous Mira K |
Grant/award | 250 | $3.83 | $958 |
Well-known investors holding BKYI (13F)
None of the 59 investors we track reported a position in their latest 13F.